title: [Acute myeloid leukemia with monosomy 7 and inv(3)(q21q26.2) complicated with central diabetes insipidus].
abstract: A 20-year-old female presented with thirst, polyposia, and polyuria and was referred to our hospital because of leukocytosis and anemia. Bone marrow aspiration revealed 66.8% myeloperoxidase-positive blasts and trilineage myelodysplasia. The karyotype was 45, XX, inv(3)(q21q26.2), -7[19]. Therefore, a diagnosis of AML with inv(3)(q21q26.2) complicated by -7 was made. Moreover, hyposthenuria and a low anti-diuretic hormone (ADH) level were observed. Although cerebrospinal fluid analysis was normal, magnetic resonance imaging (MRI) revealed the absence of hyperintensity in the neurohypophysis in T1-weighted images. Therefore, she was also diagnosed with diabetes insipidus. After she was administered a desmopressin nasal spray, the volume of urine produced decreased. Following treatment with second induction therapy containing high-dose cytarabine for AML, she achieved complete remission in the bone marrow. Moreover, when the abnormality on MRI and the volume of urine were normalized, she discontinued desmopressin. Although diabetes insipidus is a rare complication of AML, the majority of AML patients who have diabetes insipidus have the abnormal karyotypes with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and monosomy 7. Further study is required to clarify the pathogenesis and develop a strategy for the treatment of this category of AML.
authors.affiliation: Department of Hematology, Graduate School of Medicine, Osaka City University.
authors.forename: Satoru
authors.initials: S
authors.lastname: Nanno
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Hagihara
authors.forename: Manami
authors.initials: M
authors.lastname: Sakabe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okamura
authors.forename: Akiko
authors.initials: A
authors.lastname: Inaba
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nagata
authors.forename: Mitsutaka
authors.initials: M
authors.lastname: Nishimoto
authors.forename: Hideo
authors.initials: H
authors.lastname: Koh
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Nakao
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nakane
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Taro
authors.initials: T
authors.lastname: Shimono
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D002872:Chromosome Deletion; D002893:Chromosomes, Human, Pair 3; D002897:Chromosomes, Human, Pair 7; D003561:Cytarabine / Q000627:therapeutic use*; D020790:Diabetes Insipidus, Neurogenic / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D005260:Female; D006801:Humans; D007621:Karyotyping / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003561:Cytarabine